Hemocoagulase in Tumor Bleeding

• Cleaves fibrinogen, releasing fibrinopeptide A (and sometimes B), promoting formation of fibrin monomer directly at the bleeding site.
• Has a thromboplastin-like action that activates factor X to Xa, accelerating local thrombin generation.
• Stabilizes the resulting fibrin clot via an effect on factor XIIIa.
• Notably, its fibrin-forming action is not inhibited by heparin or other circulating thrombin inhibitors, which is why it can still work in patients on anticoagulation.

• Local/topical application is the better-supported approach for tumor bleeding: hemocoagulase spray applied directly at oozing sites during endoscopy (e.g., GI tumor or post-ESD bleeding) achieves hemostasis rates comparable to standard care and is particularly effective in small vessels (<1 mm diameter), with hemostasis often achieved within seconds. It is less effective for larger-vessel or brisk arterial bleeding, where clipping or electrocoagulation remains superior.
• A 2025 report describes a gelatin sponge-hemocoagulase sealant used after tumor biopsy specifically to prevent biopsy-tract bleeding, combining a mechanical barrier (sponge) with the pharmacologic clotting effect.
• It has also been used systemically (IV) perioperatively for tumor surgery (e.g., intracranial tumor resection, breast cancer surgery) to reduce surgical/postoperative blood loss and transfusion needs.

• Repeated or high-dose systemic (IV) hemocoagulase can deplete fibrinogen (hypofibrinogenemia), because it continually consumes fibrinogen to form fibrin. This is a recognized adverse effect, especially with larger cumulative doses.
• In intracranial tumor resection, larger hemocoagulase doses were associated with postoperative fibrinogen deficiency and increased transfusion requirements - the opposite of the intended effect.
• Case reports describe patients whose GI bleeding worsened after IV hemocoagulase once fibrinogen was consumed, particularly in frail or critically ill patients (e.g., an elderly patient with respiratory failure). Tumor patients often already have altered coagulation (malignancy-associated hypercoagulable or consumptive states), so fibrinogen should be monitored closely if hemocoagulase is used systemically.
• Because tumor tissue is often friable and highly vascular, relying on a systemic pro-coagulant without addressing the local lesion can give a false sense of hemostatic security.

• Best evidence supports local/topical use at the tumor bleeding site (endoscopic spray, biopsy-site sealant) as an adjunct to mechanical hemostasis, not a replacement for it.
• Systemic IV use for tumor-associated bleeding should be dose-limited and paired with fibrinogen monitoring, since hypofibrinogenemia can paradoxically worsen bleeding.
• It is not a substitute for definitive hemostatic measures (embolization, clipping, cautery, surgery) in significant tumor hemorrhage - it is best used as an adjunct for oozing/capillary-type bleeding.

• Qi X, "Hemocoagulase might not control but worsen gastrointestinal bleeding in an elderly patient" - Transl Gastroenterol Hepatol.
• Wang T et al., "Hemostatic effect of topical hemocoagulase spray in digestive endoscopy" - PMC.
• Chen X et al. 2025, "A gelatin sponge-hemocoagulase sealant for preventing tumor biopsy complications" - Frontiers in Oncology (PMID 41059301).
• Ma W et al. 2024, "Incidence, clinical features, and risk factors of hemocoagulase-induced hypofibrinogenemia" - Medicine (PMID 38608074).
• Yao YT et al. 2019, systematic review/meta-analysis on hemocoagulase reducing postoperative bleeding in cardiac surgery (PMID 31876750) - supports general hemostatic efficacy, though not tumor-specific.